

Verapamil benefits chronic rhinosinusitis with nasal polyps

January 26 2017



(HealthDay)—For patients with chronic rhinosinusitis with nasal polyps

(CRSwNP), the first-generation inhibitor of epithelial P-glycoprotein (P-gp; an efflux pump that is overexpressed in CRSwNP), verapamil hydrochloride (HCl), is associated with improvement in outcome measures, according to a letter to the editor study published online Jan. 23 in the *Journal of Allergy and Clinical Immunology*.

Marcel M. Miyake, M.D., from Harvard Medical School in Boston, and colleagues conducted a randomized placebo-controlled trial comparing oral verapamil HCl to placebo over eight weeks. Patients were followed up at weeks two, four, and eight. Eighteen [patients](#) completed the study: 10 from the verapamil group and eight from the placebo group.

The researchers found that from baseline to week eight, the least squares mean change in the validated disease-specific 22-item Sinonasal Outcome Test was -27.3 and 0.4 in the verapamil and placebo groups, respectively, resulting in a final difference between the groups of -27.7 ($P = 0.01$). The final least squares mean between-group difference in visual analogue scale score was -37.97 ($P = 0.001$). There was a significant difference favoring the verapamil group in the Lund-Mackay computed tomography score (absolute mean difference, -5.20 ; $P = 0.02$). The verapamil group also had a significant reduction in total Lund-Kennedy endoscopic score at week four (least mean squares difference of -2.8 between the groups; $P = 0.003$).

"Our data demonstrate that low-dose verapamil monotherapy is well tolerated by patients, with [fewer] side effects and lower costs than those reported in previous studies using biologic agents," the authors write.

Several authors disclosed financial ties to medical technology companies; one author provided expert testimony on ENT-related cases, and has a patent for P-gp inhibition for [chronic rhinosinusitis](#).

More information: [Full Text \(subscription or payment may be](#)

[required](#))

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Verapamil benefits chronic rhinosinusitis with nasal polyps (2017, January 26) retrieved 26 April 2024 from

<https://medicalxpress.com/news/2017-01-verapamil-benefits-chronic-rhinosinusitis-nasal.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.